Eli Lilly blows past estimates, hikes guidance

Eli Lilly reported third-quarter earnings and revenue above expectations, driven by strong sales of its weight loss drug Zepbound and diabetes treatment Mounjaro.

Shares rose more than 3% following the results.

The company raised its full-year 2025 revenue guidance to $63–63.5 billion and adjusted profit to $23–23.70 per share, up from prior estimates, CNBC has reported.

Quarterly sales for Mounjaro reached $6.52 billion, up 109% year-over-year, while Zepbound generated $3.59 billion, a 184% increase from the prior year.

read more: https://www.cnbc.com/2025/10/30/eli-lilly-lly-earnings-q3-2025.html

👍 Like this video if you’re tracking the booming weight loss and diabetes drug market.
💬 Comment below—do you think Eli Lilly can keep up this explosive growth, or will competition catch up?
🔗 Share this video to keep others informed about the biggest trends in pharma and biotech.
💰 Want to support our channel? Hit the YouTube Thanks button—your support helps us keep delivering in-depth coverage of the markets.
👉 Don’t forget to subscribe for more updates on health tech, investing, and major earnings reports.
Thanks for watching and supporting the channel.

Links for B.C.

Visit My Website
https://bcbegley.com

Follow Me On Facebook
https://www.facebook.com/B.C.Begley

Subscribe To My Patreon
https://www.patreon.com/bcbegley

Watch Me On YouTube
https://www.youtube.com/channel/UCGoUf-QQTlTN-BIh3ERCE9A

Follow Me On Twitter
https://twitter.com/BC_News1

Watch Me On Rumble
https://rumble.com/c/c-280191

Follow Me On Gab
https://gab.com/BC_Begley

Follow Me On Truth Social
https://truthsocial.com/@BC_Begley

Follow Me On BlueSky
https://bsky.app/profile/bcbegley.bsky.social

Watch Me On TikTok
https://www.tiktok.com/@bcbegley

#EliLilly #Mounjaro #Zepbound